Yahoo Web Search

Search results

1. • Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

     Zacks· 1 day ago

     Free Report) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab ...

2. • 

     Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint

     The Wall Street Journal· 4 days ago

     HEALTH NEWS Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer...

3. • 

     Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs

     BenefitsPRO· 4 days ago

     Patents are set to expire for the company's two top-selling drugs – the blood thinner Eliquis, which...

4. • Aethlon Medical Stock Surges In Pre-market On Positive Hemopurifier Trial Results

     RTT News· 4 days ago

     In pre-market activity on the Nasdaq, Aethlon shares were surging more than 101 percent to trade at $2.44. The company noted...of the Hemopurifier in patients with solid tumors who have stable ...

5. • ...Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles...

     Fairbanks Daily News-Miner· 4 days ago

     Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced ...

6. • 

     Bristol Myers Squibb reports setback in lung cancer trial By Investing.com

     Investing.com· 4 days ago

     The study evaluated the efficacy of Opdivo in combination with chemoradiotherapy, and subsequent...

7. • Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

     WFRV 5 Green Bay· 5 days ago

     In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's " ...

8. • 

     2 Beaten-Down Stocks to Buy and Hold for 10 Years

     The Motley Fool via AOL· 4 days ago

     However, the drugmaker isn't out of the woods just yet. Cancer drug Opdivo is one of the company's top-selling products, but it will ...

9. • 

     Is Eli Lilly Stock A Better Pick Over Amgen?

     Forbes· 1 day ago

     Also, Eli Lilly has seen a better revenue growth and is more profitable. There is more to the comparison, and in the sections below, we discuss why we...

10. • 

      Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.

      Quartz· 6 days ago

      Every pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...